Gotham Asset Management LLC bought a new stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,891 shares of the medical research company’s stock, valued at approximately $1,673,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Independent Portfolio Consultants Inc. boosted its position in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer boosted its position in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares in the last quarter. Penserra Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares in the last quarter. South Texas Money Management Ltd. purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at $202,000. Finally, Fairfax Financial Holdings Ltd Can purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at $206,000. 87.15% of the stock is owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.87% during midday trading on Friday, hitting $173.23. The stock had a trading volume of 2,202,642 shares. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The firm’s 50-day moving average price is $176.78 and its 200-day moving average price is $165.46. The firm has a market capitalization of $67.58 billion, a PE ratio of 30.18 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm earned $2.03 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/gotham-asset-management-llc-buys-shares-of-10891-thermo-fisher-scientific-inc-tmo/1479323.html.

TMO has been the subject of several research reports. Deutsche Bank AG raised their target price on Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, April 28th. BTIG Research raised their target price on Thermo Fisher Scientific from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Barclays PLC set a $175.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Leerink Swann set a $187.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, April 27th. Finally, Bank of America Corporation raised their target price on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $188.56.

In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the sale, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.